Mablink Bioscience
Lyons, FR· latest recorded location
MABLINK BIOSCIENCE is named on 2 US grants and 6 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 2
- Published applications
- 6
- Inventors
- 9
- Granted in 2026 so far
- 1
- Most recent grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 3 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 8 documents
Recent patents
- Antibody-drug conjugates and their uses15 Sep 2026US 12,734,244 B2
- Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload23 Sep 2025US 12,419,964 B2
- Antibody-drug conjugates and their uses13 Aug 2026US 2026/0232826 A1
- Antibody-drug conjugates and their uses2 Oct 2025US 2025/0302978 A1
- Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload24 Apr 2025US 2025/0127916 A1
- Ligand-drug-conjugate comprising a single molecular weight polysarcosine20 Feb 2025US 2025/0057964 A1
- Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties4 Jul 2024US 2024/0216525 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.